An open, parallel-group, randomised, multi-centre phase IIIstudy to compare the long-term (52-week) safety of Symbicort(budesonide/ formoterol) pMDI 160/4.5 mcg 2 actuations b.i.d. withthat of Symbicort Turbuhaler 160/4.5 mcg 2 inhalations b.i.d. inadults and adolescents with asthma

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting [email protected].

*Please Note* The Study information you are attempting to view is not available on ClinicalTrials.gov as the Study predates the Food and Drug Administration Amendments Act (FDAAA), Section 801 requirements. More information regarding this study may be available by contacting [email protected].